Beam Therapeutics Inc. buy thesis: base-editing gene therapy leaders, risto-cel & BEAM-302 catalysts, strong cash runway.

Precision gene-editing company Beam Therapeutics (NASDAQ: BEAM) had a Tuesday to forget on the stock market. Following the release that morning of its latest set of quarterly results, the shares raced ...

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to a loss of $1.09 per share a year ago. These ...

Beam Therapeutics BEAM shares are rising Tuesday after the company reported quarterly results. Beam Therapeutics stock is ...

Beam stock launched to a 10-month high Monday after the company reached a deal with the Food and Drug Administration for its gene-editing drug, BEAM-302. Beam TherapeuticsBEAM is testing its drug in ...

Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the top gene therapy stocks to buy according to hedge funds. On February 25, ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Beam Therapeutics Inc. (BEAM) is a stock that can certainly grab ...

Beam Therapeutics is a biotech firm focused on developing precision genetic treatments using base editing technology. The company has secured $675 million in upfront payments from agreements with ...

A Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has early signs of efficacy along with safety data that ease some concerns about ...